Next earnings date: 21 Oct 2025
Simulations Plus, Inc. – NASDAQ:SLP
Founder-led company
Simulations Plus stock price today
$13.87
-14.79
-51.61%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Simulations Plus stock price monthly change
-31.71%
month
Simulations Plus stock price quarterly change
-31.71%
quarter
Simulations Plus stock price yearly change
-36.83%
year
Simulations Plus key metrics
Market Cap | 568.30M |
Enterprise value | 566.34M |
P/E | 57.98 |
EV/Sales | 8.08 |
EV/EBITDA | 48.01 |
Price/Sales | 8.22 |
Price/Book | 3.15 |
PEG ratio | -3.42 |
EPS | 0.58 |
Revenue | 68.71M |
EBITDA | 12.50M |
Income | 11.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 14.16% |
Oper. margin | 8.76% |
Gross margin | 61.63% |
EBIT margin | 8.76% |
EBITDA margin | 18.2% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSimulations Plus stock price history
Simulations Plus stock forecast
Simulations Plus financial statements
| May 2023 | 16.23M | 4.00M | 24.69% |
|---|---|---|---|
| Aug 2023 | 15.62M | 534K | 3.42% |
| Feb 2024 | 18.30M | 4.02M | 22.01% |
| May 2024 | 18.54M | 3.13M | 16.92% |
| Aug 2025 | 23.36M | 3.68M | 15.76% |
|---|---|---|---|
| Aug 2025 | 18.97M | 6.08M | 32.06% |
| Nov 2025 | 22.97M | 2.45M | 10.7% |
| Mar 2026 | 28.64M | 6.75M | 23.58% |
Analysts Price target
Financials & Ratios estimates
0.62%
Yield TTM
| Payout ratio | 48.39% |
|---|
| 2020 | 0.4% |
|---|---|
| 2021 | 0.54% |
| 2022 | 0.4% |
| 2023 | 0.54% |
| 2024 | 0.66% |
| May 2023 | 179134000 | 9.74M | 5.44% |
|---|---|---|---|
| Aug 2023 | 186101000 | 16.07M | 8.64% |
| Feb 2024 | 193973000 | 16.93M | 8.73% |
| May 2024 | 192691000 | 11.83M | 6.14% |
| May 2023 | 8.54M | 7.91M | -628K |
|---|---|---|---|
| Aug 2023 | 3.06M | 520K | -1.18M |
| Feb 2024 | 5.81M | -7.51M | -1.05M |
| May 2024 | 5.68M | 69.91M | -3.53M |
Simulations Plus alternative data
| Aug 2023 | 157 |
|---|---|
| Sep 2023 | 157 |
| Oct 2023 | 157 |
| Nov 2023 | 157 |
| Dec 2023 | 192 |
| Jan 2024 | 192 |
| Feb 2024 | 192 |
| Mar 2024 | 192 |
| Apr 2024 | 192 |
| May 2024 | 192 |
| Jun 2024 | 192 |
| Jul 2024 | 192 |
Simulations Plus other data
70.47%
-29.53%
of SLP is owned by hedge funds
141
-6
14.61M
-79.66K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 21000 |
| Feb 2024 | 0 | 20000 |
| Mar 2024 | 0 | 20000 |
| Apr 2024 | 0 | 20000 |
| May 2024 | 0 | 27400 |
| Jun 2024 | 0 | 21400 |
| Jul 2024 | 0 | 20000 |
| Aug 2024 | 0 | 20000 |
| Sep 2024 | 0 | 21400 |
| Oct 2024 | 0 | 20000 |
| Nov 2024 | 0 | 20000 |
| Dec 2024 | 0 | 20650 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | WOLTOSZ WALTER S director, 10 perc.. | Common Stock | 20,000 | $31.76 | $635,200 | ||
Sale | LAVANGE LISA director | Common Stock | 650 | $31.88 | $20,722 | ||
Sale | WOLTOSZ WALTER S director, 10 perc.. | Common Stock | 20,000 | $27.66 | $553,200 | ||
Sale | WOLTOSZ WALTER S director, 10 perc.. | Common Stock | 20,000 | $31.26 | $625,200 | ||
Sale | WEINER DANIEL L director | Common Stock | 750 | $31.54 | $23,655 | ||
Option | FIEDLER-KELLY JILL officer: Business Unit President | Common Stock | 2,250 | $9.71 | $21,848 | ||
Option | FIEDLER-KELLY JILL officer: Business Unit President | Employee Stock Option (Right to Buy) | 2,250 | $9.71 | $21,848 | ||
Sale | WOLTOSZ WALTER S director, 10 perc.. | Common Stock | 18,042 | $35.13 | $633,815 | ||
Sale | WOLTOSZ WALTER S director, 10 perc.. | Common Stock | 1,958 | $35.68 | $69,861 | ||
Sale | LAVANGE LISA director | Common Stock | 650 | $35.95 | $23,368 |
| Quarter | Transcript |
|---|---|
| Q2 2024 3 Apr 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 3 Jan 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 25 Oct 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Jul 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Shawn M. O'Connor (1960) Chief Executive Officer | $544,230 |
| Mr. William Frederick (1964) Chief Financial Officer & Sec. | $371,700 |
Mr. John Anthony DiBella M.S. (1980) Pres of Lancaster Division | $312,150 |
| Mr. Walter S. Woltosz (1945) Co-Founder & Chairman | $91,040 |
Simulations Plus: Benefiting From FDA Modernization And AI
Simulations Plus: Overhyped With No Growth Left
Simulations Plus: Differentiated Offering For Speculators Of Clinical-Stage Assets
Simulations Plus: In The Spotlight
Simulations Plus: Bullish Into Long-Term Earnings Runway
Simulations Plus: Software For The Pharma Industry, Significant Upside Potential
Simulations Plus: Ample Momentum In Software Segment To Drive More Gains
Simulations Plus: Growth Speculation, Buy The Dip In This Drug Testing Company
Searching For Wonderful Businesses: Simulations Plus
-
What's the price of Simulations Plus stock today?
One share of Simulations Plus stock can currently be purchased for approximately $13.87.
-
When is Simulations Plus's next earnings date?
Simulations Plus, Inc. is estimated to report earnings on Tuesday, 21 Oct 2025.
-
Does Simulations Plus pay dividends?
Yes, Simulations Plus pays dividends and its trailing 12-month yield is 0.63% with 48% payout ratio. The last Simulations Plus stock dividend of $0.06 was paid on 7 Feb 2022.
-
How much money does Simulations Plus make?
Simulations Plus has a market capitalization of 568.30M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 17.52% to 70.01M US dollars.
-
What is Simulations Plus's stock symbol?
Simulations Plus, Inc. is traded on the NASDAQ under the ticker symbol "SLP".
-
What is Simulations Plus's primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of Simulations Plus?
Shares of Simulations Plus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Simulations Plus's key executives?
Simulations Plus's management team includes the following people:
- Mr. Shawn M. O'Connor Chief Executive Officer(age: 65, pay: $544,230)
- Mr. William Frederick Chief Financial Officer & Sec.(age: 61, pay: $371,700)
- Mr. John Anthony DiBella M.S. Pres of Lancaster Division(age: 45, pay: $312,150)
- Mr. Walter S. Woltosz Co-Founder & Chairman(age: 80, pay: $91,040)
-
Is Simulations Plus founder-led company?
Yes, Simulations Plus is a company led by its founder Mr. Walter S. Woltosz.
-
How many employees does Simulations Plus have?
As Jul 2024, Simulations Plus employs 192 workers.
-
When Simulations Plus went public?
Simulations Plus, Inc. is publicly traded company for more then 28 years since IPO on 18 Jun 1997.
-
What is Simulations Plus's official website?
The official website for Simulations Plus is simulations-plus.com.
-
Where are Simulations Plus's headquarters?
Simulations Plus is headquartered at 42505 Tenth Street West, Lancaster, CA.
-
How can i contact Simulations Plus?
Simulations Plus's mailing address is 42505 Tenth Street West, Lancaster, CA and company can be reached via phone at +66 17 237 723.
Simulations Plus company profile:
Simulations Plus, Inc.
simulations-plus.comExchange:
NASDAQ
Full time employees:
243
Industry:
Medical - Healthcare Information Services
Sector:
Healthcare
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
42505 Tenth Street West
Lancaster, CA 93534-7059
Lancaster, CA 93534-7059
CIK: 0001023459
ISIN: US8292141053
CUSIP: 829214105
